In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Class Action Claims Often Follow Regulatory Action, Industry Litigation

This article was originally published in The Tan Sheet

Executive Summary

FDA warning letters, FTC consent orders, Lanham Act litigation and National Advertising Division reviews all provide fodder for attorneys looking to bring consumer product lawsuits. While some case settlements come with large monetary payments, injunctive components also are common and often costly.

You may also be interested in...



Class Action ‘Extortion’ Demands Defense From First Step In Litigation – Attorneys

Companies targeted in class actions should challenge litigants throughout the process, from when a complaint is filed to when a judge is deciding, say lawyers during a Council for Responsible Nutrition webinar. Firms fearful of high damage fees too often will settle when they have other options.

Class Action ‘Extortion’ Demands Defense From First Step In Litigation – Attorneys

Companies targeted in class actions should challenge litigants throughout the process, from when a complaint is filed to when a judge is deciding, say lawyers during a Council for Responsible Nutrition webinar. Firms fearful of high damage fees too often will settle when they have other options.

Supplement Class Action Complaints Down So Far In 2014

From January to June, complaints against supplement firms accounted for 12% of total U.S. filings alleging unfair and deceptive acts and practices, compared with 18% for all of 2013, according to law firm Bryan Cave.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS105531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel